Obesity and NASH: The Bugs don’t Work. Or do They?
Insights on the Gut Microbiome, Obesity, and NAFLD: Part I The human gastrointestinal (GI) tract is home to trillions of microorganisms, often... In DRG Blog/ November, 2018 Does Bad News Mean the Blues for Bempedoic Acid?
Esperion Therapeutics’ lead candidate, bempedoic acid, a novel cholesterol-lowering agent, has made steady progress and could meet an important... In DRG Blog/ May, 2018 The Obesity Market 2017: Year in Review
Overall, 2017 was not exactly a stellar year for the obesity drug market, with more downs than ups, and although the unmet need for novel drug... In DRG Blog/ February, 2018 Global NASH Congress 2018: Regulators and the Race to Drug Approval
Non-alcoholic steatohepatitis (NASH) is fast becoming a highly competitive drug development race; the high prevalence of the disease, the substantial... In DRG Blog/ February, 2018 The NASH Market 2017: Year in Review
Some substance was added to all the hype around non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) in 2017. New drug... In DRG Blog/ February, 2018 The Dyslipidemia Market 2017: Year in Review
Although 2017 was not awash with exciting novel therapies or practice-changing research, the importance of managing lipid levels to reduce the risk of... In DRG Blog/ February, 2018 Bempedoic Acid: A Statin Equivalent for the Statin Intolerant
The statin class provided a major breakthrough for managing high cholesterol, a key modifiable risk factor for cardiovascular (CV) disease, and are... In DRG Blog, Drug Watch/ November, 2017